Actively Recruiting
Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
Led by Shanghai Zhongshan Hospital · Updated on 2025-12-15
50
Participants Needed
1
Research Sites
282 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being done to analyze the safety, tolerability, and efficacy of treatment using combination of anti-VEGF and anti-PD-1/PDL1 antibodies for patients with advanced hepatocellular carcinoma.
CONDITIONS
Official Title
Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, male or female
- Diagnosed with advanced hepatocellular carcinoma that cannot be removed or has spread
- At least one measurable tumor lesion without local treatment
- Child-Pugh Class A liver function
- Barcelona Clinic Liver Cancer (BCLC) stage B or C
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Provided written informed consent
- Adequate function of important organs
- Expected survival of at least 12 weeks
- Use of medically accepted contraception during the study and for 3 months after treatment if of childbearing potential
You will not qualify if you...
- Active or history of autoimmune diseases such as autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroid hyperfunction, vitiligo, or asthma requiring medical intervention
- Use of immunosuppressive agents or systemic hormonal therapy exceeding 10 mg/day prednisone or equivalent within 2 weeks before enrollment
- Presence of uncontrolled clinical symptoms or diseases
- Significant bleeding symptoms or bleeding tendency within 3 months prior to randomization
- Arterial or venous thrombosis within 6 months prior to randomization
- Factors affecting study results or safety such as alcohol or drug abuse, serious diseases including mental illness, or serious laboratory abnormalities
- Liver tumor burden exceeding 50% of total liver volume
- Previous liver transplantation
- History of central nervous system metastasis or hepatic encephalopathy
- Severe allergic reactions to other monoclonal antibodies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital Fudan university
Shanghai, China
Actively Recruiting
Research Team
W
Wenxin Xu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here